AI Chips Today - AI Advancements Revolutionize Drug Discovery and Cancer Treatment
Complete. Here is the key summaryVERAXA Biotech and Ardigen partnered to integrate AI into drug discovery, targeting cancer treatments via the BiTAC pipeline. In market news, GlobalWafers rose 10%, while SK hynix fell 14.7%. Major chip stocks saw mixed results: NVIDIA gained 4%, whereas Broadcom and Micron declined slightly.
Recent developments in the AI chip sector include a notable collaboration between VERAXA Biotech and Ardigen. This partnership focuses on integrating artificial intelligence into drug discovery processes to enhance VERAXA's BiTAC pipeline, targeting cancer treatments. The AI will aid in selecting synergistic cancer target pairs, potentially improving therapeutic outcomes by reducing toxicity and systemic effects. This initiative highlights the growing role of AI chips in revolutionizing precision medicine and drug development by optimizing data analysis and therapeutic design.
Elsewhere in the market, GlobalWafers (TPEX:6488) was a standout up 10% and ending the day at NT$1,485.00. In the meantime, SK hynix (KOSE:A000660) softened, down 14.7% to end trading at ₩1,859,000.
Seize the opportunity in SK hynix's AI-driven premium pricing and margin expansion; click to explore the comprehensive narrative on their strategic advancements.
Don't miss our Market Insights article on AI Chips where we analyzed the dominating AI trade in recent Q1 earnings.
Best AI Chip Stocks
- NVIDIA (NasdaqGS:NVDA) closed at $210.96 up 4%.
- Broadcom (NasdaqGS:AVGO) settled at $399.97 down 0.3%.
- Micron Technology (NasdaqGS:MU) ended the day at $979.30 down 1.2%.
Key Takeaways
- Unlock more gems! Our AI Chip Stocks screener has unearthed 134 more companies like Tower Semiconductor, BIWIN Storage Technology and GRINM Semiconductor Materials for you to explore.
- Searching for a Fresh Perspective? The end of cancer? These 33 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Sources:
- Simply Wall St
- "VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline" from Veraxa Biotech AG on GlobeNewswire (published 13 July 2026)
Valuation is complex, but we're here to simplify it.
Discover if NVIDIA might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free Analysis
